Relationship between the efficacy of rivastigmine and apolipoprotein E (ε4) in patients with mild to moderately severe Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 20, Issue 4, 2006, Pages 248-254

  Blesa, Rafael ^a   Aguilar, Miquel ^b   Casanova, Jordi Peña ^c   Boada, Mercé ^d   Martínez, Sergi ^a   Alom, Jordi ^e   De La Hoz, Carlos Hernández ^f   Sancho, Jerónimo ^g   Fernández, Óscar ^h   Gil Neciga, Eulogio ⁱ   Massó, Jose Félix Martí ^j  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d Fundacion ACE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g Hospital Gral de Valencia   (Spain)

^h Hospital Gral   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j Hospital Nuestra Senora de Aranzazu   (Spain)

more..

Author keywords

Alzheimer disease; Apolipoprotein E; Open label; Rivastigmine

Indexed keywords

APOLIPOPROTEIN E EPSILON2; APOLIPOPROTEIN E EPSILON3; APOLIPOPROTEIN E EPSILON4; APOLIPOPROTEIN E4; RIVASTIGMINE;

AGED; ALLELE; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CHROMOSOME 19; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DNA POLYMORPHISM; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; DRUG RESISTANCE; FEMALE; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 33845406615     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000213880.93665.c7     Document Type: Article

References (39)

1. Katzman R. Alzheimer's disease. N Engl J Med. 1986;314:964-973.
2. Ems RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1262-1264.
3. Max W. The economic impact of Alzheimer's disease. Neurology. 1993;43:6-10.
4. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology. 2006;66(suppl 1):S79-S85.
5. Gene M, Moreno P, Ezquerra M, et al. Low apolipoprotein E epsilon4 allele frequency in the population of Catalonia (Spain) determined by PCR-RFLP and laser fluorescent sequence. Eur J Epidemiol. 1997;23:841-843.
6. Adroer R, Santacruz P, Blesa R, et al. Apoliprotein E4 allele frequency in Spanish Alzheimer and control cases. Neurosci Lett. 1995;189:182-186.
7. Lopex OL, Lopez-Pousa S, Kamboh MI, et al. Apolipoprotein E polymorphism in Alzheimer's disease: a comparative study of two research populations from Spain and the United States.
8. Blesa R, Adroer R, Santacruz P, et al. High apolipoprotein E epsilon 4 allele frequency in age-related memory decline. Am Neurol. 1996;39:548-551.
9. Small BJ, Graves AB, McEvoy CL, et al. Is APOE ε4 a risk factor for cognitive impairement in normal aging? Neurology. 2000;54:2082-2088.
10. Liddell MB, Lovestone S, Owen MJ. Genetic risk of Alzheimer's disease: advising relatives. Br J Psychiatry. 2001;178:7-11.
11. Holtzman DM, Fagan AM, Mackey B, et al. Apoliprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's Disease Model. Ann Neurol. 2000;47:739-747.
12. Ramachandran G, Marder K, Tang M, et al. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer disease. Neurology. 1996;47:256-259.
13. López-Pousa S, Lombardía C. Tratamiento de la Enfermedad de Alzheimer: fármacos inhibidores de la enzima colinesterasa. Neurología. 1999;14:182-188.
14. Almkvist O, Darreh-Shori T, Stefanova E, et al. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur J Neurol. 2004;11:253-261.
15. Farlow M, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000;44:236-241.
16. Corey-Bloom J, Anand R, Veach J. For the ENA 713 (rivastigmine tartrate) B352 Study Group. A randomised trial evaluating the efficacy and safety of ENA-713, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geristr Psychopharmacol. 1998;1:55-65.
17. Rösler M, Anand R, Cicin-Sain A, et al. On behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: results of an international, 26 week, multicentre, randomised, palcebo-controlled trial. BMJ. 1999;318:633-640.
18. Spencer CM, Nobre S. Rivastigmina: revisión de su empleo en la enfermedad de Alzheimer. Drugs Aging. 1998;13:391-413.
19. Farlow MR, Lahiri DK, Poirier J, et al. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann NY Acad Sci. 1996;802:101-110.
20. Poirier J, Deslie MC, Quirion R, et al. Apolipropotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad USA. 1995;92:12260-12264.
21. Rigaud AD, Traikov L, Caputo L, et al. The apolipoprotein E epsilon 4 allele and the reponse to tacrine therapy in Alzheimer's disease. Eur J Neurol. 2000;7:255-258.
22. Farlow MR, Cyrus PA, Nadel A, et al. Metrifonate treatment of AD: influence of APOE genotype. Neurology. 1999;53:2010-2016.
23. Raskind MA, Peskind ER, Wessel T, et al. Galantamine USA-1 Study Group. A six month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
24. Polymeropolus MH. No association between ApoE4 carrier status and response to Rivastigmine in Alzheimer's Disease. bmj.com eLetters for Bentam et al. 319(7210)640, 19 June 2000.
25. Visser PJ, Scheltens P, Pelgrim E, et al. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. Dementia Geriatr Cogn Dis. 2004;19:126-133.
26. Farlow M, Lane R, Kudaravalli S, et al. Differential qualitative responses to rivastigmine in APOE ε4 carriers and noncarriers. Pharmacogenomics J. 2004;4:332-335.
27. Stefanova E, Blennow K, Almkvist O, et al. Cerebral glucose metabolism, cerebrospinal fluid β-amyloid (1-42), tau and APOE genotype in long-term rivastigmine and tacrine treated Alzheimer disease patients. Neurosci Lett. 2003;338:159-163.
28. Lanctot KL, Herrmann N, LouLou MM. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci. 2003;28:13-26.
29. Wenham PR, Sedky A, Spooner RJ. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991;337:1150-1158.
30. Peña-Casanova J, Aguilar M, Santacruz P, et al., and NORMACODEM Group. Adaptación y normalización españolas de la Alzheimeŕs Disease Assessment Scale (ADAS) (NORMACODEM) (y II). Neurología. 1997;12:69-77.
31. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral grey matter of elderly subjects. Br J Psychiatr. 1968;114:797-811.
32. Reisberg B, Ferris SH, de León MJ. The global deterioration scale (GDS): an instrument for the assessment of primary degenerative dementia (PDD). Am J Psychiatry. 1982;139:1136-1139.
33. Escobar JL, Burnam A, Karno M, et al. Use of the Mini-Mental State Examination (MMSE) in a community population of mixed ethnicity. Cultural and linguistic artifacts. J Nerv Mental Dis. 1986;174:607-614.
34. Vilalta-Franch J, Lozano-Gallego M, Hernández-Ferrandiz M, et al. Inventario Neuropsiquiatrico. Propiedades Psicometricas de la adaptación Española. Rev Neurol. 1999;29:15-19.
35. Alvarez V, Alvarez R, Pena J, et al. Frecuencia del alelo APOE-4 en la enfermedad de Alzheimer en la población Asturiana y su variación con la edad. Med Clin (Barcelona). 1999;113:441-443.
36. Cummings JL. Cholinesterase inhibitors: expanding applications. Lancet. 2000;356:2024-2025.
37. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric and functional impairment in Alzheimer disease: a metaanalysis. JAMA. 2003;289:210-216.
38. McKeith I, Del Ser T, Spano PF, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-bind, placebo-controlled international study. Lancet. 2000;356:2031-2036.
39. Almkvist O, Jelic V, Amberia K, et al. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double blind-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord. 2001;12:22-32.